Frontiers LL37 driven mast cell degranulation and inflammation in rosacea via TLR2 JAK2 STAT3 axis Mast CellTargeting Therapies in Mast Cell Activation Syndromes Current Allergy and Asthma Reports Springer Nature Link Read this paper describing a large case series of patients with mast cell activation syndrome (MCAS) and comorbidities, whose MCAS associated symptoms improved significantly on GLP1 agonists. To summarize: 47 Frontiers LL37 driven mast cell degranulation and inflammation in rosacea via TLR2 JAK2 STAT3 axis